A Phase III Randomized, Open-label Study Comparing GSK1120212 to Chemotherapy in Subjects With Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 29 Mar 2017
At a glance
- Drugs Trametinib (Primary) ; Dacarbazine; Paclitaxel; Vemurafenib
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Acronyms METRIC
- Sponsors GlaxoSmithKline; Novartis Pharma A.G.
- 07 Jun 2017 Biomarkers information updated
- 25 Mar 2017 This trial has been completed in Greece (end date: 16 Dec 2016).
- 12 Mar 2017 This trial was completed in Belgium, according to European Clinical Trials Database.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History